Midi Health vs Revvity
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $100M Series D (Feb 2026) at $1B unicorn valuation. 230K+ patients in 50 states. Digital health's first menopause-focused unicorn. Expanding to longevity and cardiology.
About
Midi Health became digital health's first menopause-focused unicorn in February 2026, raising $100 million in Series D financing at a $1 billion valuation. The company serves 230,000+ patients across all 50 states with clinician-led care for menopause, perimenopause, and midlife women's health — a market that has been systematically underserved by mainstream healthcare despite affecting 50 million American women.
Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.
About
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.